Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
Taysha reported positive longer-term data from the REVEAL trials for TSHA-102, showing 100% of Part A patients (N=12) gained or regained at least one developmental milestone by 12 months post-treatment. Safety remained favorable with no treatment-related serious adverse events or dose-limiting toxicities observed across the 29 patients dosed in the REVEAL pivotal and Phase 1/2 trials.
Key figures
- Drug Name
- TSHA-102
- Phase Of Trial
- REVEAL Phase 1/2 and pivotal
- Part a patients
- 12
- Safety dlt count
- 0
- Safety sae count
- 0
- Total functional gains 12m
- 310
- Milestone response rate 12m
- 100%
- Pivotal trial patients dosed
- 17
- Avg functional gains per patient
- 26
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.